看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。/ b. P) E# u% Z, `7 @. X( A/ N) Q) Z
Q/ }5 T, u5 D; B* f* x# ~1 W2 O. s! z( \
Currently available feasibility data for possible combination strategies.
$ c D( n+ D; o————————————————————————————————: M, l1 g7 `3 Y+ Q% Y
Combination Feasibility according to preliminary data
3 a% h) K7 C7 Q3 e9 e% A# `——————————————————————————————————: h3 I: v* |( N1 J3 N6 |
Bevacizumab + sorafenib Yes, reduced dose
o5 c$ d3 S& h' A* CBevacizumab + sunitinib† No : @$ n3 Q' @6 v+ P2 H' M8 v: G
Bevacizumab + temsirolimus Yes
, Y5 Y: t& P# B' L3 u _Bevacizumab + everolimus Yes
- a' P$ N2 ` }# m4 m6 y; GSorafenib + sunitinib ? 8 m+ K3 J, I, O' F, }6 G
Sorafenib + temsirolimus Yes, reduced dose
- m+ x {, q" Z; U, @Sorafenib + everolimus Yes, reduced dose
2 R( A0 b* r5 y" e4 YSunitinib + temsirolimus† No
7 P! X. t2 {% V; A: wSunitinib + everolimus ? 1 Q9 d; K3 @0 Z W
Temsirolimus + everolimus ?
" _+ _+ x& M3 X! d" h$ U/ D———————————————————— D" ^' h% @# r) [8 H) k( d
†Led to US FDA warning.
3 v T+ J) s0 U- J- M* H [ W8 v% P?: As yet unattempted combination.
7 M0 u8 w$ U6 B |